Sionna Therapeutics, Inc. (SION) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Sionna Therapeutics, Inc. (SION) closed at USD 4.08 on 2026-10-15, a change of -89.1 % over the past year, with a market capitalization of USD 175.63M.

Sionna Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sionna Therapeutics, Inc. key figures

Previous close

USD 4.08 (2026-10-15)

1-year change

-89.1 %

Market cap

USD 175.63M

Enterprise value

USD -27.09M

P/E ratio (trailing)

-1.80

P/E ratio (forward)

-1.74

EPS (trailing)

-2.16

EPS (forward)

-2.23

PEG ratio

n/a

Price to book

0.66

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.55

Employees

59

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sionna Therapeutics, Inc. and compare it with other stocks.